Eczema Action Plans: Do They Improve Objective Disease Outcomes?

Clicks: 1
ID: 315246
2026
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal

Ranked #121 of 172 articles by views in clinical and experimental dermatology

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 172 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Abstract
Abstract Eczema action plans have emerged as a management tool for eczema. Recent studies investigated the efficacy of the eczema action plans in improving quality of life and disease severity. This study aims to examine the effectiveness of eczema action plans in improving eczema. A search was conducted using MEDLINE, EMBASE, and SCOPUS databases for clinical trials evaluating eczema action plans in eczema management. Five studies (four randomized, one non-randomized) showed no objective improvement in atopic dermatitis severity or quality of life with eczema action plans. Eczema action plans improved patient knowledge, confidence, and satisfaction, but these did not translate to clinical outcomes, possibly due to complex regimens hindering adherence.
Reference Key
openalex_W7162779680 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Priya kadu, Chenan Huang, Matthew Zirwas, Steven R Feldman
Journal clinical and experimental dermatology
Year 2026
DOI
10.1093/ced/llag226
URL
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

No comments yet. Be the first to comment on this article.